Cancer Research

Cancer is a term used to define a group of diseases in which abnormal cells divide without control, are able to invade neighboring tissues/organs and metastasize. Cancer has been characterized by six hallmarks; self sufficiency in proliferative growth signals, insensitivity to growth inhibitors, evasion of apoptosis, limitless replicative potential, ability to develop blood vessels (angiogenesis), and tissue invasion and metastasis.

Cancer Research Products Areas

Products for Cancer Research - Page 79

Cat.No. Product Name Information/Activity
BCC7406 CD 1530 107430-66-0
BCC6071 CD 2314 170355-37-0
BCC7110 CD 437 CD437 is a selective Retinoic Acid Receptor γ (RARγ) agonist.
BCC7241 Ch 55 Ch55 is a potent synthetic retinoid. Ch55 binds to RAR-α and RAR-β receptors with high affinity. Ch55 displays low affinity for cellular retinoic acid binding protein (CRABP). Ch55 is a potent inducer of the differentiation of HL60 cells with an EC50 of 200 nM. Ch55 can be used for cancer research.
BCC2284 Isotretinoin Isotretinoin(13-cis-Retinoic acid) is a medication used for the treatment of severe acne.
BCN2185 Retinoic acid Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM.
BCC2540 Tazarotene Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris.
BCC4874 TTNPB (Arotinoid Acid) TTNPB is a highly potent RAR agonist. Competitive binding assays using human RARs yield IC50s of α=5.1 nM, β= 4.5 nM, and γ=9.3 nM, respectively.
BCC7740 BMS 195614 253310-42-8
BCC7697 BMS 493 BMS493 is an inverse pan-retinoic acid receptor (RAR) agonist. BMS493 increases nuclear corepressor interaction with RARs. BMS493 also could prevent retinoic acid-induced differentiation.